Icu Medical Inc/de

ICU Medical announced strong second quarter 2026 results, exceeding expectations for Infusion Systems and generally meeting them for other segments, leading to an upward revision of its full-year financial guidance.

ICU Medical, Inc. announced that its stockholders approved significant amendments to its Certificate of Incorporation, including a shift to simple majority voting and a 25% threshold for calling special meetings.

ICU Medical announced its first quarter 2026 financial results, showing a GAAP revenue decline but a non-GAAP organic revenue increase, with adjusted EBITDA slightly down year-over-year.

ICU Medical announced its fourth quarter 2025 financial results, reporting a revenue decline to $540.7 million and a GAAP net loss of $(15.7) million, while providing fiscal year 2026 guidance.

ICU Medical, Inc. announced its third quarter 2025 financial results, reporting a significant reduction in GAAP net loss and an increase in adjusted diluted EPS, leading to an upward revision of its full fiscal year 2025 guidance.

ICU Medical, Inc. reported a significant swing to GAAP net income in Q2 2025, alongside improved gross margins and adjusted profitability, despite a decline in overall revenue.

ICU Medical Inc. announced its second-quarter results, showcasing significant revenue increases in Infusion Systems and Consumables, alongside a notable improvement in gross margins driven by tariff refunds and strategic divestitures.

ICU Medical reports improved profitability and significant debt reduction in Q3 2025, despite a revenue decline and ongoing regulatory and tariff pressures.

ICU Medical reports a return to net income and improved gross margins in Q2 2025, driven by the strategic divestiture of its IV Solutions business and significant debt reduction, despite an overall revenue decline and new FDA regulatory challenges.

ICU Medical's Q1 2025 shows revenue growth driven by consumables and infusion systems, but the company still reports a net loss due to restructuring and integration expenses.

ICU Medical saw a revenue increase in Q3 2024, but experienced a net loss, influenced by restructuring and integration expenses, and a valuation allowance against deferred tax assets.

ICU Medical's second quarter results show a net loss despite revenue growth, influenced by restructuring, integration costs, and foreign exchange impacts.

ICU Medical reported a net income of $0.732 million for fiscal year 2025, a significant improvement from prior losses, driven by strategic divestitures and gross margin expansion, despite a revenue decline and ongoing FDA regulatory challenges.

ICU Medical's 2024 10-K filing reveals a complex financial landscape, marked by strategic acquisitions, global economic challenges, and ongoing efforts to optimize operations and navigate regulatory hurdles.

ICU Medical's 2023 10-K filing reveals a complex financial landscape marked by global economic pressures, strategic integration efforts, and regulatory compliance in the medical device industry.

Daniel Woolson, VP, GM-Infusion Capital of Icu Medical Inc/De, sold 5,417 shares of common stock on August 13, 2026 for $181.33 per share.

Ben Sousa, Chief Information Officer of Icu Medical Inc/De, sold 2,250 shares of common stock on August 12, 2026 for $178.32 per share.

Christian B. Voigtlander, Chief Operating Officer of Icu Medical Inc/De, sold 8,929 shares of common stock on August 11, 2026 for $182.93 per share.

Elisha W Finney, a Director of Icu Medical Inc/De, sold 378 shares of common stock on August 11, 2026 for $182.48 per share.

ICU Medical President Daniel Woolson sold 2,123 shares of common stock on May 22, 2026.

Virginia Ruth Sanzone, VP and General Counsel of ICU Medical, Inc., reported a sale of 2,447 shares of common stock on May 14, 2026.

ICU Medical's 2026 proxy statement reveals mixed 2025 financial performance, significant regulatory challenges, and proposed corporate governance enhancements.

ICU Medical, Inc. has filed a proxy statement with the Securities and Exchange Commission (SEC) in compliance with Section 14(a) of the Securities Exchange Act of 1934.

ICU Medical is asking stockholders to approve an amendment to its stock incentive plan to increase the number of shares available for issuance.

ICU Medical, Inc. has filed a definitive proxy statement with the SEC.

ICU Medical, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 15, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

Fuller & Thaler Asset Management, Inc. has disclosed a beneficial ownership of 5.19% of ICU Medical, Inc.'s common stock as of June 30, 2026.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of ICU Medical, Inc. common stock to 11.1%.

Fuller & Thaler Asset Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4.94% of ICU Medical Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.19% of ICU Medical Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.82% of ICU Medical Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership of ICU Medical Inc. common stock following an internal realignment.